TY - JOUR
T1 - Guanidine Derivative ADS1017, a Potent Histamine H3 Receptor Antagonist with Promising Analgesic Activity and Satisfactory Safety Profile
AU - Karcz, Tadeusz
AU - Szczepańska, Katarzyna
AU - Mogilski, Szczepan
AU - Moroz, Aleksandra
AU - Olejarz-Maciej, Agnieszka
AU - Humphrys, Laura J.
AU - Pockes, Steffen
AU - Siwek, Agata
AU - Dubiel, Krzysztof
AU - Staszewski, Marek
AU - Calmels, Thierry
AU - Waczyński, Krzysztof
AU - Kieć-Kononowicz, Katarzyna
N1 - Publisher Copyright:
© 2024 American Chemical Society.
PY - 2024/12
Y1 - 2024/12
N2 - In this study, we selected 12 guanidine derivatives from the previously described ligand library and determined their affinity at histamine H3 and H4 receptors (H3R and H4R, respectively). Moreover, we also checked their intrinsic activity toward H3R and muscarinic M1, M2, and M4 receptors (M1R, M2R, and M4R, respectively). Since ADS1017 has been proved to be the most selective and highly potent H3 antagonist in our series, we chose it as the lead structure for further biological evaluation. To extend the study of its in vivo efficacy, we proposed an alternative synthetic route that resulted in an increased yield. Interestingly, ADS1017 showed a broad spectrum of analgesic activity in both nociceptive and neuropathic pain models. Finally, as a result of comprehensive analysis of its off-target activity and ADMETox parameters, we confirmed the moderate selectivity of ADS1017 and its promising drug-like properties.
AB - In this study, we selected 12 guanidine derivatives from the previously described ligand library and determined their affinity at histamine H3 and H4 receptors (H3R and H4R, respectively). Moreover, we also checked their intrinsic activity toward H3R and muscarinic M1, M2, and M4 receptors (M1R, M2R, and M4R, respectively). Since ADS1017 has been proved to be the most selective and highly potent H3 antagonist in our series, we chose it as the lead structure for further biological evaluation. To extend the study of its in vivo efficacy, we proposed an alternative synthetic route that resulted in an increased yield. Interestingly, ADS1017 showed a broad spectrum of analgesic activity in both nociceptive and neuropathic pain models. Finally, as a result of comprehensive analysis of its off-target activity and ADMETox parameters, we confirmed the moderate selectivity of ADS1017 and its promising drug-like properties.
KW - ADMETox properties
KW - functional characterization
KW - guanidines
KW - histamine H receptor
KW - multi-target directed ligand
KW - muscarinic receptors
KW - pain
UR - http://www.scopus.com/inward/record.url?scp=85211497884&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.4c00480
DO - 10.1021/acschemneuro.4c00480
M3 - Article
C2 - 39652796
AN - SCOPUS:85211497884
SN - 1948-7193
VL - 15
SP - 4441
EP - 4457
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 24
ER -